Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jun 04, 2024 12:58pm
163 Views
Post# 36071443

RE:RE:RE:New options

RE:RE:RE:New options

Just my humble opinion a few things.
Brad Tompson has not been with ONC for over 5 years. Not sure what is being quoted, referred to etc.
Secondly, just like the company using the ATM. The dillution mantra is a red herring.
The only time share count would matter , would be on a buyout.
Regarding our resident fool, proclaiming a delisting?
As discussed. 
Oncy would have to trade continuously under $1, for over a month of trading days.
Then they would receive notice of compliance. Giving at that time 90 dats to comply or issue a plan of compliance.
At that point, there is an additional 3 month waiting period.
adding up to close to a year.
Astor even one day, Oncy closes above $1 within all of those warnings, reminders etc. The whole process starts over.
As our simpleton says, just the facts.
i have been around, Oncy did previously trade well under $1. That being around 2017.
They did issue a public notice of compliance.
I spoke with them then I.R. Guy , Michael Moore.
That was long before the presnt dsy MBc FDA meeting, Roche gobblet Panc trial, enforced by CGAR.
The upcoming next arm of trials to start.
" first patient to be enrolled this quarter".
meaning next few weeks.
Mr. Moore explained the process to me. I may be a bit off in the exact time windows.
His bottom line. they would have to trade un- interrupted under $1, for almost a year, to be delisted.
I know Bucky is hard core shorting. He dreams up scenarios, which are easily refuted & claims them to be facts.
My " opinion" onc has a greater chance of being bought out, than delisted.
The science last few months, including the $5 million grant from PanCan, is evidence of that.
The SP goes up & down. 
The TSX lost 100 points yesterday.
perhaps thst is ONCs management fault...lol
 

 

<< Previous
Bullboard Posts
Next >>